Dr. Clay Siegall is a US-based biotechnology researcher who serves as the CEO of Seattle Genetics. He co-founded the company, and he has been using it to positively impact the pharmaceuticals industry by developing great drugs for cancer. Seattle Genetics is an innovative company and has created various advanced biogenetics technologies. It has also been committed to manufacturing excellent medications that can help in curing cancer patients across the globe. It has developed ADCs, which have so far increased the motility rate of cancer patients.
Clay Siegall has played a great role in the growth of Seattle Genetics. He led the firm in having its first IPO about one and a half decades ago. To date, the biotechnology research hub has successfully generated more than $670 million through public and private funding programs. Clay had gained sufficient experience by working for different corporations before the establishment of Seatle Genetics. He started conducting his biotechnology research by serving a government body that is called the National Cancer Institute. In 1991, Siegall was employed by the Bristol-Myers Squib Pharmaceutical Research Institute, and he served as a senior researcher until 1997. The Alder Biopharmaceuticals, Biomedical Association, Ultragenynx Pharmaceutical, and Washington Roundtable appointed him to sit on their board of directors.
The research undertakings of Clay Siegal at Seattle Genetics have been beneficial to the pharmaceuticals sector. He has managed to secure 15 patents for the drugs that he has developed. Siegal has also published about 70 scientific books that are used for reference by students and professionals. He schooled at the George Washington University where he got his Ph.D. and also attended the University of Maryland for his first degree.
Dr. Siegal has used his biotechnology and genetics expertise to assist Seattle Genetics in developing the ADCs technology. The company has currently commercialized more than 20 drugs that are sold across the world. The manufacture and distribution of the drugs have been made possible by partnering with leading corporations such as Bayer, Takeda Pharmaceutical Company, and Genentech. The chemotherapies that are currently used in curing cancer have serious effects such as hair loss, and therefore, Clay has been striving to establish better drugs.